Last reviewed · How we verify

NCT04696094

The Role of m6A RNA Modification in Moyamoya Disease

Status unknown Last updated 17 February 2022
What this trial tests

trial in Moyamoya Disease in 160 participants. Status unknown.

Timeline
1 January 2021
Primary endpoint
31 December 2022
31 December 2022

Quick facts

Lead sponsorBeijing Tiantan Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment160
Start date1 January 2021
Primary completion31 December 2022
Estimated completion31 December 2022
Sites1 location across China

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 4 to 60, any sex, with Moyamoya Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to detect the change of m6A RNA modification from peripheral blood of patients with moyamoya disease, and to assess the relationship between clinical characteristics.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effects of RNA methylation on Tumor angiogenesis and cancer progression.
    Han M, Sun H, Zhou Q, Liu J, et al · · 2023 · cited 37× · PMID 38053093 · DOI 10.1186/s12943-023-01879-8

Verify or expand the search:

Other recruiting trials for Moyamoya Disease

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04696094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing